Business Wire

TOSHIBA

27.8.2020 07:02:11 CEST | Business Wire | Press release

Share
Toshiba’s New Photorelays Contribute to Equipment Downsizing by Reducing Mounting Density

Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched three photorelays: “TLP3407SRA ,” “TLP3475SRHA ” and “TLP3412SRHA ,” that are the industry-smallest[1] voltage driven photorelays with an extended operating temperature rating of 125°C.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005815/en/

Raising the maximum operating temperature rating from 110°C to 125°C allows the photorelays to be mounted in high temperature areas, and makes it easier to secure required temperature design margins for equipment. The S-VSON4T package has the industry-smallest[1] mounting area of 2.9mm² .This will contribute to reducing PCB size or to increasing the number of photorelays in an existing layout in applications such as semiconductor testers, probe cards and other devices.

Applications

  • Semiconductor testers (memory, SoC and LSI, etc.)
  • Probe cards
  • Burn-in equipment
  • Measuring instruments (oscilloscope, data logger, etc.)

Features

  • S-VSON4T, the industry’s first[1] packaging with a minimal mounting area and maximum operating temperature of 125°C: Mounting area 2.9mm2 (typ.)
  • Low input power consumption drive: 3.3mW[2] (max) @VIN =3.3V (TLP3407SRA)

Main Specifications

(@Ta =25℃)

Part number

TLP3407SRA

TLP3475SRHA

TLP3412SRHA

Package

Name

S-VSON4T

Size typ. (mm)

2.0×1.45

Height typ.(mm)

1.3

Recommended
operating
conditions

Applied input

forward voltage

VIN  typ. (V)

3.3

3.3

3.3

Built-in resistance typ. (Ω)

4000

600

600

Absolute

maximum

ratings

OFF-state output

terminal voltage VOFF (V)

60

60

60

ON-state current ION (A)

1

0.4

0.4

ON-state current (pulsed)

IONP (A)

3

1.2

1.2

Operating temperature

Topr (℃)

-40 to 125

Coupled
electrical
characteristics

Limited LED current 

ILIM(LED) max (mA)

(@VIN )

1
(@3.3V)

-

-

Trigger LED current

IFT max (mA)

0.2

2

2

Operating voltage

 VFON max (V)

3

3

3

ON-state resistance

RON max (Ω)

0.3

1.5

1.5

Electrical

characteristics

Output capacitance

COFF typ. (pF)

80

12

20 (max)

OFF-state current

IOFF max (nA)

(@VOFF )

1

(@50V)

1

(@50V)

1

(@50V)

Switching

characteristics

Turn-on time

tON max (ms)

20

0.5

0.5

Turn-off time

tOFF max (ms)

1

0.2

0.2

Isolation

characteristic

Isolation voltage

BVS min (Vrms)

500

500

500

Sample Check & Availability

Buy Online

Buy Online

Buy Online

Notes:
[1] For photorelays where maximum operating temperature rating is 125°C, according to a survey by Toshiba (as of August 25, 2020).
[2] Applied input forward voltage × maximum limited LED current=3.3V×1mA

Follow the link below for more on the new photocouplers.
TLP3407SRA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3407SRA

TLP3475SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3475SRHA

TLP3412SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3412SRHA

Follow the link below for more on Toshiba’s photorelay lineup.
https://toshiba.semicon-storage.com/ap-en/semiconductor/product/optoelectronics/photorelay-mosfet-output.html

To check availability of the new products at online distributors, visit:
TLP3407SRA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3407SRA.html
TLP3475SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3475SRHA.html
TLP3412SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3412SRHA.html

Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel: +81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html

* Company names, product names, and service names may be trademarks of their respective companies.
* Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.

About Toshiba Electronic Devices & Storage Corporation

Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, the company has taken its place among the leading general devices companies, and offers its customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.

Its 24,000 employees around the world share a determination to maximize the value of its products, and emphasize close collaboration with customers to promote co-creation of value and new markets. The company looks forward to building on annual sales now surpassing 750-billion yen (US$6.8 billion) and to contributing to a better future for people everywhere.
Find out more about Toshiba Electronic Devices & Storage Corporation at https://toshiba.semicon-storage.com/ap-en/top.html

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye